No Advantage to the Addition of Platinol® to Camptosar®/5-FU for Advanced Gastric Cancer (4/3/2008)
Researchers from Korea have reported that the addition of Platinol® (cisplatin) to Camptosar® (irinotecan), 5-FU, and leucovorin for the treatment of patients with gastric cancer offers no survival benefit. These findings were published in the April 2008 issue of the Annals of Oncology.

Chlorhexidine or Oral Cooling Decrease Chemotherapy-induced Mucositis (3/31/2008)
Researchers from Denmark have reported that chlorhexidine mouth washes or oral cooling decreases the incidence and severity of oral mucositis associated with 5 FU and leucovorin-based chemotherapy for gastrointestinal cancer. The details of this randomized study appeared in an early online publication in Cancer on February 15, 2008.

Combination of Chemotherapy and Immunotherapy Shows Promise for Gastric Cancer (3/28/2008)
Researchers from South Korea have reported that a combination of chemotherapy and immunotherapy may improve overall survival of patients with locally advanced gastric cancer undergoing curative surgery. The details of this randomized Phase III trial were published in the March, 2008 issue of the Annals of Oncology.

S-1 Plus Platinol® Effective for Advanced Gastric Cancer (2/22/2008)
Researchers from Japan have reported that the combination of S-1 plus Platinol® (cisplatin) is superior to S-1 alone for the treatment of advanced gastric cancer. The details of this study appeared in an early online publication on February 18, 2008, in Lancet Oncology.

Adjuvant Therapy with New Oral Fluoropyrimidine Improves Survival for Resected Gastric Cancer (11/7/2007)
Researchers from Japan have reported that an oral fluoropyrimidine, S-1, improves survival by 10% in patients with resected stage II-III gastric cancer. The details of this study were published in the November 1, 2007 issue of the New England Journal of Medicine.